Semnur Pharmaceuticals Announces Binding $100 Million Term Sheet for Strategic Investment
Semnur Pharmaceuticals entered into a binding term sheet for a $100 million strategic equity investment from iHolding Group LLP. This capital injection aims to support the continued development of its late-stage pain therapies, particularly the SEMDEXA Phase 3 program.
View filing at SEC.gov →